---
document_datetime: 2025-09-17 10:29:03
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pemetrexed-pfizer-previously-pemetrexed-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pemetrexed-pfizer-previously-pemetrexed-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.4120004
conversion_datetime: 2025-12-25 00:07:45.038297
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pemetrexed Pfizer

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | B.II.b.2.cReplacementor additionofa | 11/09/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000278463                     | manufacturerresponsibleforimportation and/or batch release - B.1I.b.2.c.1 Not includingbatchcontrol/testing-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            | PL                     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| Variation type IB / EMA/VR/0000263141 | C.I.2 Change(s) in the Summary of Product Characteristics,LabellingorPackageLeaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for thereference product-C.I.2.a Implementation of change(s) for which no new additional data is required to be submittedbytheMAH-Accepted Type IB (C.1.2.a) - To update section 4.2, 4.5 in line with the originator product ALIMTA,following theconclusion of EMEA/H/C/PSUSA/0002330/202402.Section 2 of the Package Leaflet was updated accordingly.Inaddition,theMAHtookthe opportunity to align the EL, IT, LT, NL, PT, SK,andFI annexesto thoseofthe originator's. | 25/04/2025 | SmPC, Labelling and PL |